吉利德科学(GILD)周二盘后大涨5.32%,引发市场关注。公司公布的2024年第四季度业绩数据喜人,成为暴涨主因。
数据显示,吉利德公司第四季度调整后每股收益1.90美元,超出华尔街预期的1.70美元。营收达到75.7亿美元,也高于分析师71.4亿美元的预期。公司预计2025年调整后每股收益在7.70至8.10美元之间,产品销售额在282至286亿美元区间,较今年将实现增长。
就具体产品而言,吉利德的艾滋病特效药物Biktarvy在第四季度的销售额达到38亿美元,同比大增21%,继续保持强劲增长态势。尽管丙肝药物Veklury销售额出现下滑,但其他抗肿瘤和肝病药物实现了增长。值得注意的是,在中国市场,吉利德的丙肝泛基因型复方制剂丙通沙(Epclusa)依然占据主导地位,助其在该细分领域保持竞争优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.